| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 203 companies in the Health Care Equipment & Supplies industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 13, 2022 | HAE Haemonetics Corp | Basil Michelle L51 | EVP And General Counsel | Sell | 277 | $62.60 | $17,340.20 | -0.7% | +24.0% | +36.9% | |
| Jun 13, 2022 | Toloue Masoud57 | President &CEO | Sell | 5,564 | $15.27 | $84,955.05 | -6.4% | -30.1% | +52.7% | ||
| Jun 13, 2022 | AHCO Adapthealth Corp. | Skyknight Capital Fund Ii, L.P.53 | Director | Buy | 100,000 | $17.22 | $1,722,010.00 | +3.4% | +15.2% | -41.0% | |
| Jun 13, 2022 | ECOR Electrocore, Inc. | Errico Joseph P59 | Director | Buy | 100,000 | $0.56 | $55,780.00 | +6.0% | -5.6% | -46.0% | |
| Jun 13, 2022 | MASS 908 Devices Inc. | Griffith Joseph H. IV81 | Chief Financial Officer | Sell | 13,334 | $13.54 | $180,542.36 | -12.7% | +44.0% | -31.0% | |
| Jun 13, 2022 | QSI Quantum-Si Inc | Dyer Matthew | Chief Business Officer | Sell | 1,622 | $3.22 | $5,222.84 | -0.5% | +17.5% | -43.4% | |
| Jun 13, 2022 | HAE Haemonetics Corp | Goldstein Dan | VP, Corporate Controller | Sell | 42 | $62.60 | $2,629.20 | -0.9% | +24.0% | +36.9% | |
| Jun 13, 2022 | WRBY Warby Parker Inc. | Miller Steven Clive62 | Chief Financial Officer | Sell | 12,137 | $13.93 | $169,093.01 | -3.6% | +16.9% | -10.7% | |
| Jun 10, 2022 | NMTC Neuroone Medical Technologies Corp | McClurg Ronald W.74 | Chief Financial Officer | Buy | 14,000 | $1.06 | $14,781.20 | +32.6% | +64.5% | +15.0% | |
| Jun 10, 2022 | WRBY Warby Parker Inc. | Gilboa David Abraham62 | Co-chief Executive Officer | Sell | 5,224 | $14.64 | $76,479.36 | -95.7% | -1.9% | -20.2% | |
| Jun 10, 2022 | WRBY Warby Parker Inc. | Blumenthal Neil Harris66 | Co-chief Executive Officer | Sell | 5,224 | $14.64 | $76,479.36 | -98.0% | -1.9% | -20.2% | |
| Jun 10, 2022 | TELA Tela Bio, Inc. | Opaleye Management Inc.60 | 10% Owner | Buy | 27,500 | $5.60 | $154,066.00 | +1.8% | +55.5% | +92.3% | |
| Jun 10, 2022 | NVCR Novocure Ltd | Hilleman Jeryl L61 | Director | Sell | 407 | $69.61 | $28,331.27 | -13.8% | +25.0% | -38.4% | |
| Jun 10, 2022 | AHCO Adapthealth Corp. | Skyknight Capital Fund Ii, L.P.53 | Director | Buy | 13,922 | $17.44 | $242,756.23 | +0.2% | +5.9% | -42.9% | |
| Jun 10, 2022 | ATEC Alphatec Holdings, Inc. | Segal Paul69 | 10% Owner | Buy | 71,329 | $7.18 | $512,126.22 | +17.6% | +7.8% | +104.6% | |
| Jun 10, 2022 | TELA Tela Bio, Inc. | Ew Healthcare Partners Fund 2, L.P.57 | See Footnote 2 | Buy | 15,000 | $5.98 | $89,750.00 | +0.1% | +55.5% | +92.3% | |
| Jun 9, 2022 | ATEC Alphatec Holdings, Inc. | Berkowitz Mortimer III | Director | Buy | 16,000 | $7.20 | $115,200.00 | +3.0% | +6.9% | +110.0% | |
| Jun 9, 2022 | CTSO Cytosorbents Corp | Chan Phillip P.56 | Chief Executive Officer | Buy | 16,000 | $2.17 | $34,784.00 | +2.1% | -20.6% | +52.8% | |
| Jun 9, 2022 | CATX Perspective Therapeutics, Inc. | Austin Mark John | VP Finance/ Prin Fin&Acct Offic | Buy | 18,800 | $0.29 | $5,384.22 | +24.9% | +21.1% | +81.2% | |
| Jun 8, 2022 | NPCE Neuropace Inc | Ridley Irina46 | General Counsel And Secretary | Sell | 2,500 | $5.78 | $14,445.00 | -3.9% | -17.2% | -27.2% | |
| Jun 8, 2022 | TNDM Tandem Diabetes Care Inc | Berger David B79 | EVP &Chief Operating Officer | Sell | 10,097 | $65.02 | $656,515.00 | -55.8% | -33.7% | -63.4% | |
| Jun 8, 2022 | CATX Perspective Therapeutics, Inc. | Hunt Jonathan Robert61 | Chief Financial Officer | Buy | 39,000 | $0.29 | $11,160.86 | +26.4% | +18.1% | +83.7% | |
| Jun 8, 2022 | LFWD Lifeward Ltd. | Dykan Jeff | Director | Buy | 25,000 | $1.02 | $25,400.00 | +69.0% | -10.5% | -43.6% | |
| Jun 7, 2022 | BDX Becton Dickinson & Co | Spoerel Thomas J58 | VP Controller &Chief Acct Off | Sell | 443 | $260.00 | $115,180.00 | -29.5% | -1.9% | -0.8% | |
| Jun 7, 2022 | SERA Sera Prognostics, Inc. | Boniface John J.55 | Chief Scientific Officer | Sell | 2,725 | $1.30 | $3,542.50 | -4.0% | +30.0% | +146.2% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.